DOCSLIB.ORG

Effects of Glucose on Endothelial Function in Pregnancy and the Influence of Diabetes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Glucose on Endothelial Function in Pregnancy and the Influence of Diabetes EFFECTS OF GLUCOSE ON ENDOTHELIAL FUNCTION IN PREGNANCY AND THE INFLUENCE OF DIABETES A thesis submitted to The University of Manchester for the degree of PhD in the Faculty of Medical and Human Sciences 2006 Haiju Henry Chirayath School of Medicine LIST OF CONTENTS ABSTRACT 17 CHAPTER 1: INTRODUCTION 26 1.1 Diabetes Mellitus 27 1.1.1 Background 27 1.1.2 Rationale of study 28 1.1.3 Definition of diabetes 28 1.1.4 Classification of diabetes 29 1.1.5 Diagnosis of diabetes 29 1.1.6 Type 1 diabetes 30 1.1.7 Type 1 diabetes in pregnancy 31 1.1.8 Type 2 diabetes 31 1.1.9 Type 2 diabetes in pregnancy 32 1.1.10 Gestational diabetes 32 1.1.10.1 Definition and diagnosis 32 1.1.10.2 Features of gestational diabetes 35 1.1.11 Other specific types of diabetes 36 1.2 Animal models of diabetes 36 1.2.1 Animal models of type 1 diabetes 37 1.2.2 Animal models of type 2 diabetes 37 1.2.3 Animal models of diabetes in pregnancy 37 1.2.4 Advantages of animal models of diabetes 38 1.2.5 Limitations of animal models of diabetes 38 1.3 Pregnancy 39 1.3.1 Carbohydrate metabolism in pregnancy 39 1.3.2 Cardiovascular changes in pregnancy 40 1.4 Arteries 41 1.4.1 Blood flow to the fetus 41 1.4.2 Resistance arteries 41 2 1.5 The Endothelium 42 1.5.1 Endothelial function 42 1.5.2 Endothelium-dependent mediators of relaxation 43 1.5.2.1 Nitric Oxide 44 1.5.2.2 Prostacyclin 45 1.5.2.3 Endothelium Derived Hyperpolarizing Factor 46 1.5.3 Endothelium-derived vasoconstrictors 47 1.5.4 Other factors affecting endothelial function 48 1.5.4.1 Age 48 1.5.4.2 Smoking 48 1.5.4.3 Ethnicity 48 1.5.4.4 Cholesterol 48 1.5.5 Endothelial function in pregnancy 48 1.5.6 Methods of measuring endothelial function 49 1.5.6.1 Venous occlusion plethysmography 50 1.5.6.2 Brachial artery flow-mediated vasodilation 50 1.5.6.3 Limitations of brachial artery FMD 51 1.6 Endothelial dysfunction in diabetes 51 1.6.1 Animal studies of endothelial dysfunction in diabetes 52 1.6.2 Human studies of endothelial dysfunction in diabetes 52 1.6.3 Mechanisms of endothelial dysfunction in diabetes 53 1.6.4 Endothelial dysfunction and regional variations 55 1.6.5 Other factors influencing endothelial dysfunction in diabetes 56 1.6.5.1 Control of diabetes 56 1.6.5.2 Obesity 56 1.6.5.3 Lipids 57 1.6.5.4 Insulin resistance 58 1.6.5.5 Gender differences in diabetes 58 1.7 Endothelial dysfunction of diabetes in pregnancy 58 1.7.1 Type 1 diabetes 58 1.7.2 Gestational diabetes 59 1.7.3 Previous gestational diabetes 59 1.8 Glucose levels 61 1.8.1 HbA1C 62 3 1.9 Hyperglycaemia 62 1.9.1 Definition 62 1.9.2 Estimating hyperglycaemia 62 1.9.3 Degree of hyperglycaemia 63 1.9.4 Duration of hyperglycaemia 63 1.9.5 Pathophysiology of hyperglycaemia 64 1.9.5.1 Oxidative stress 64 1.9.5.2 Hyperglycaemia and endothelial mediators 66 1.9.6 Acute Hyperglycaemia 66 1.9.7 Hyperglycaemia and endothelium-dependent relaxation 67 1.10 Hypoglycaemia 69 1.10.1 Hypoglycaemia and pregnancy 69 1.10.2 Hypoglycaemia and endothelial function 70 1.11 Blood glucose in pregnancy 70 1.12 Summary of Introduction 72 1.13 Hypotheses 73 1.14 Aims 73 CHAPTER 2 MATERIALS AND METHODS 74 2.1 Ethics 75 2.2 Human subjects 75 2.2.1 Healthy women 75 2.2.1.1 Non-pregnant women 75 2.2.1.2 Pregnant women 75 2.2.2 Diabetic patients 75 2.2.2.1 Type 1 and type 2 diabetes in pregnancy 75 2.2.2.2 Gestational diabetes 76 2.3 Mice 76 2.4 Tissue Collection 76 2.4.1 Non-pregnant women 76 2.4.2 Pregnant women 77 2.4.3 Mice 77 4 2.5 Stereomicroscopic dissection 77 2.6 Resistance arteries 77 2.7 Choice of methodology 77 2.8 Wire myography 78 2.8.1 Multi Myograph System 610M 79 2.8.2 Advantages of wire myography 80 2.8.3 Limitations of wire myography 81 2.9 Normalisation of vessel lumen 81 2.10 Drugs 82 2.10.1 Potassium chloride 82 2.10.2 Bradykinin 82 2.10.3 Phenylephrine 83 2.10.4 Acetylcholine 83 2.10.5 U46619 83 2.10.6 L-NNA 83 2.10.7 Indomethacin 83 2.10.8 Streptozotocin 83 2.10.9 Choice of drugs 84 2.10.9.1 Vasoconstriction 84 2.10.9.2 Endothelium-dependent relaxation 84 2.11 Solutions 85 2.11.1 Glucose physiological saline solutions 85 2.11.2 60 mmol/L KPSS 85 2.11.3 Hyper-osmolar solution 86 2.11.4 Modified Krebs’ buffer 86 2.12 Experimental protocols 86 2.12.1 Protocol 1: The effect of glucose levels on maximum constriction 86 2.12.2 Protocol 2: The effect of glucose levels on endothelium-dependent relaxation 88 2.12.3 Protocol 3: The effect of hyper-osmolarity 89 2.12.4 Protocol 4: The effect of blockers to endothelium-dependent relaxation 90 5 2.13 Optimising experiments 92 2.13.1 General measures 92 2.13.2 Optimising mice experiments 92 2.14 Creating an animal model of diabetes 93 2.14.1 Restrictions in human research 93 2.14.2 Rationale for creating an animal model of diabetes 94 2.14.3 Obtaining a Home Office Licence 94 2.14.4 Species and strain 94 2.14.5 Duration of diabetes 95 2.14.6 Diabetogenic drug 95 2.14.7 Procedure 95 2.15.8 Impediments in creating an animal model of diabetes 96 2.15 Data analysis 97 2.15.1 Constriction 97 2.15.2 Endothelium-dependent relaxation 97 2.16 Statistical analysis 97 2.16.1 General Principles 97 2.16.2 Statistical analysis of data from patients 98 2.16.3 Statistical analysis of myography data 98 2.16.3.1 Constriction 98 2.16.3.1 Endothelium-dependent relaxation 98 CHAPTER 3 THE GLUCOSE LEVELS OF WOMEN WITH DIABETES IN PREGNANCY 99 3.1 Introduction 100 3.2 Aims 101 3.3 Methodology 101 3.3.1 Inclusion criteria 102 3.3.2 Exclusion criteria 102 3.3.3 Data collection 103 3.3.4 Statistical analysis 103 6 3.4 Results 103 3.4.1 Clinical characteristics 103 3.4.2 Glucose levels 106 3.4.3 Glucose levels of type 1 diabetes in pregnancy 107 3.4.4 Glucose levels of type 2 diabetes in pregnancy 108 3.4.5 Glucose levels of gestational diabetes 108 3.4.6 HbA1C levels: comparison across types 112 3.4.7 HbA1C levels in each group 112 3.4.7.1 Type 1 diabetes 112 3.4.7.2 Type 2 diabetes 112 3.4.7.3 Gestational diabetes. 112 3.4.8 Glucose levels in GDM: effect of insulin 114 3.4.9 Glucose levels and outcomes in type 1 diabetes 116 3.4.10 HbA1C and outcomes in type 1 diabetes 116 3.5 Discussion 119 3.5.1 Glucose levels of women with diabetes in pregnancy 119 3.5.2 Glucose levels in type 1 diabetes 120 3.5.3 Glucose levels in type 2 diabetes 120 3.5.4 Glucose levels in gestational diabetes 120 3.5.5 Adverse outcomes 120 3.5.5.1 Type 1 and 2 diabetes 121 3.5.5.2 Gestational diabetes 122 3.5.6 HbA1C and glucose levels 122 3.5.7 Limitations of study 123 3.5.8 Summary 123 CHAPTER 4 THE EFFECT OF GLUCOSE ON ENDOTHELIAL FUNCTION IN HEALTHY NON-PREGNANT AND PREGNANT WOMEN 125 4.1 Introduction 126 4.2 Aims 127 4.3 Materials and Methods 127 4.4 Results 128 7 4.4.1 Clinical characteristics 128 4.4.2 Arterial diameters 129 4.4.3 Constriction: effect of glucose (non-pregnant group - KCl) 131 4.4.4 Endothelium-dependent relaxation: effect of glucose (non-pregnant group – KCl) 131 4.4.5 Constriction: effect of glucose (non-pregnant group - U46619) 131 4.4.6 Endothelium-dependent relaxation: effect of glucose (non-pregnant group – U46619) 131 4.4.7 Constriction: effect of glucose (pregnant group - KCl) 136 4.4.8 Endothelium-dependent relaxation: effect of glucose (pregnant group – KCl) 136 4.4.9 Constriction: effect of glucose (pregnant group–U46619) 139 4.4.10 Endothelium-dependent relaxation: effect of glucose (pregnant group – U46619) 139 4.4.11 Comparison of endothelium-dependent relaxation in non-pregnant and pregnant groups 144 4.4.12 Effect of prolonged exposure (2 hours) of 2, 5, 8 and 12 mmol/L glucose 146 4.5 Discussion 148 4.5.1 Summary of results 148 4.5.2 Low glucose concentration and impaired relaxation 148 4.5.2.1 The effect of vasoconstrictors 149 4.5.2.2 The effect of pregnancy 150 4.5.3 Other findings 150 4.5.3.1 Constriction 150 4.5.3.2 Effect of pregnancy on endothelium-dependent relaxation 150 4.5.3.3 Effect of prolonged incubation 151 4.5.3.4 High glucose concentrations 152 4.5.4 Explanations for the lack of effect of high glucose levels 152 4.5.4.1 Inadequate duration of high glucose levels 152 4.5.4.2 Inadequate degree of high glucose levels 152 4.5.4.3 Systemic factors 153 8 4.5.4.4 Endothelial vasodilators 154 4.5.4.5 Bradykinin 154 4.5.4.6 Branch-order 155 4.5.4.7 Age 155 4.5.4.8 Nature of vascular bed 156 4.5.4.9 Gender 156 4.5.4 Summary 157 CHAPTER 5 THE EFFECT OF GLUCOSE ON ENDOTHELIAL FUNCTION IN DIABETES COMPLICATING PREGNANCY 158 5.1 Introduction 159 5.2 Aims 160 5.3 Materials and methods 161 5.4 Results 161 5.4.1 Clinical characteristics – gestational diabetes 161 5.4.2 Diameter of arteries – gestational diabetes 163 5.4.3 Constriction: effect of glucose (GDM-KCl) 163 5.4.4 Endothelium-dependent relaxation: effect of glucose (GDM-KCl) 166 5.4.5 Constriction: effect of glucose (GDM-U46619) 166 5.4.6 Endothelium-dependent relaxation: effect of glucose (GDM-U46619) 166 5.4.7 GDM: effect of vasoconstrictor on endothelium-dependent relaxation 170 5.4.8 Constriction: effect of glucose (type 1 and 2 diabetes) 171 5.4.9 Endothelium-dependent relaxation: effect of glucose (type 1 and 2 diabetes) 171 5.4.10 Comparison between GDM and healthy pregnant women constriction 175 5.4.10.1 Using KCl 175 5.4.10.2 Using U46619 175 9 5.4.11 Comparison between GDM and healthy pregnant women: endothelium-dependent relaxation 175 5.4.11.1 Using KCl 175 5.4.11.2 Using U46619 175 5.5 Discussion 179 5.5.1 Summary of results 179 5.5.2 Endothelial dysfunction in GDM 180 5.5.2.1 Explanations for impaired relaxation 180 5.5.2.2 Implications of findings 182 5.5.2.3 Limitations of study 183 5.5.3 Patient characteristics 183 5.5.4 The effect of
Load more

Recommended publications
  • Early Endothelial Dysfunction Severely Impairs Skin Blood Flow
    Early Endothelial Dysfunction Severely Impairs Skin Blood Flow Response to Local Pressure Application in Streptozotocin-Induced Diabetic Mice Dominique Sigaudo-Roussel, Claire Demiot, Be´renge`re Fromy, Audrey Koı¨tka, Georges Lefthe´riotis, Pierre Abraham, and Jean Louis Saumet Pressure-induced vasodilation (PIV) is a mechanism al. (2) demonstrated a major role for vasodilators such as whereby skin blood flow increases in response to pro- the calcitonin gene–related peptide and endothelial vaso- gressive locally applied pressure. Skin blood flow in dilators such as nitric oxide (NO) and prostaglandins in response to applied pressure decreased early in diabetic animal studies. In a recent study, we observed in diabetic patients as a result of vascular and/or neural impair- patients an early decrease of skin blood flow in response ment. This study was designed to determine the effect of to locally applied pressure that could be involved in the vascular changes on PIV in 1-week streptozotocin-in- development of diabetic ulceration (3). However, it was duced diabetic mice. We assessed cutaneous microvas- cular response to local increasing pressure application unclear whether skin blood flow alteration during diabetes measured by laser Doppler flowmetry (LDF) and endo- depends directly on vascular and/or neural alterations. thelium-dependent and -independent vasodilation by Diabetes through hyperglycemia is widely known to be iontophoretic delivery of acetylcholine and sodium ni- a major factor that leads to microvascular and neural troprusside and sciatic motor nerve conduction velocity complications (4). Indeed, hyperglycemia-induced end- and morphometry. In control mice, LDF increased 34% organ damage in diabetes is associated with increased flux from baseline to 0.2 kPa external pressure, showing PIV of glucose through 1) the polyol metabolic pathway response.
    [Show full text]
  • Diabetic Retinopathy in Nigerians
    Brit. J. Ophthal. (I969) 53, 652 Br J Ophthalmol: first published as 10.1136/bjo.53.10.652 on 1 October 1969. Downloaded from Diabetic retinopathy in Nigerians A study of 758 patients B. 0. OSUNTOKUN Department of Medicine, University College Hospital, Ibadan, Nigeria Diabetes mellitus is a fascinating and challenging disease in African subjects. Certain aspects of the disease in Africans, especially with regard to aetiology, clinical pattern, details of management, and the incidence of some of its complications, show striking differences compared with those in Caucasian patients. Careful study of the disease may provide information not only on the aetiology of the disease, but also on its natural history and the pathogenesis ofits complications, which may be ofworld-wide importance (Tulloch, I966). Diabetic retinopathy is one such complication. In the more developed countries such as the United States of America, diabetic retino- copyright. pathy is rapidly becoming the single most important cause of blindness among the adult population. It accounted for about I8 per cent. of blindness in some states in I957/8 (Marble, I965) and the percentage ofall blindness due to diabetic retinopathy in the USA is 8-4. There is a similar incidence of diabetic retinopathy as a cause of blindness in the United Kingdom (Winter, I960). Diabetic retinopathy is not uncommon among the Bantus in South Africa (Jackson, Goldin, and Marine, I966), whereas among Nigerians it is rare (Kinnear, I963; Greenwood and Taylor, I968). This study has been carried http://bjo.bmj.com/ out to determine accurately the incidence of retinopathy in Nigerian diabetics and to delineate the various factors which may account for its rarity.
    [Show full text]
  • Health Plan Insights
    Health Plan Insights September 2020 Updates from August 2020 Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 1 Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Blenrep GlaxoSmithKline Injection, For the treatment of adult patients with August 5, 2020 (belantamab 2.5 mg/kg relapsed or refractory multiple myeloma who mafodotin-blmf) have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Lampit Bayer Healthcare Tablets, For use in pediatric patients (birth to less than August 6, 2020 (nifurtimox) 30 mg and 120 18 years of age and weighing at least 2.5 kg) mg for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi. Olinvyk Trevena, Inc. Injection, For use in adults for the management of August 7, 2020 (oliceridine) 1 mg/mL acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Evrysdi Genentech, Inc. Oral Solution, For the treatment of spinal muscular atrophy August 7, 2020 (risdiplam) 0.75 mg/mL (SMA) in patients 2 months of age and older. Viltepso NS Pharma, Inc. Injection, For the treatment of Duchenne muscular August 12, 2020 (viltolarsen) 50 mg/mL dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
    [Show full text]
  • Rxoutlook® 4Th Quarter 2020
    ® RxOutlook 4th Quarter 2020 optum.com/optumrx a RxOutlook 4th Quarter 2020 While COVID-19 vaccines draw most attention, multiple “firsts” are expected from the pipeline in 1Q:2021 Great attention is being given to pipeline drugs that are being rapidly developed for the treatment or prevention of SARS- CoV-19 (COVID-19) infection, particularly two vaccines that are likely to receive emergency use authorization (EUA) from the Food and Drug Administration (FDA) in the near future. Earlier this year, FDA issued a Guidance for Industry that indicated the FDA expected any vaccine for COVID-19 to have at least 50% efficacy in preventing COVID-19. In November, two manufacturers, Pfizer and Moderna, released top-line results from interim analyses of their investigational COVID-19 vaccines. Pfizer stated their vaccine, BNT162b2 had demonstrated > 90% efficacy. Several days later, Moderna stated their vaccine, mRNA-1273, had demonstrated 94% efficacy. Many unknowns still exist, such as the durability of response, vaccine performance in vulnerable sub-populations, safety, and tolerability in the short and long term. Considering the first U.S. case of COVID-19 was detected less than 12 months ago, the fact that two vaccines have far exceeded the FDA’s guidance and are poised to earn EUA clearance, is remarkable. If the final data indicates a positive risk vs. benefit profile and supports final FDA clearance, there may be lessons from this accelerated development timeline that could be applied to the larger drug development pipeline in the future. Meanwhile, drug development in other areas continues. In this edition of RxOutlook, we highlight 12 key pipeline drugs with potential to launch by the end of the first quarter of 2021.
    [Show full text]
  • North Carolina Division of Health Benefits Physician Administered Drug Program Catalog
    North Carolina Division of Health Benefits Physician Administered Drug Program Catalog North Carolina Division of Health Benefits Physician Administered Drug Program Catalog •Unless otherwise indicated, the catalog contains procedure codes representing drugs, biologics, devices and vaccines which are only covered for FDA approved indications. Covered indications that are not FDA approved are identified with **. •11 digit National Drug Codes (NDCs) are required to be billed along with their corresponding procedure code. Drugs and biologics must be classified as CMS covered outpatient drugs from a labeler/manufacturer participating in the Medicaid Drug Rebate Program (MDRP). •The Max Daily Units for radiopharmaceuticals represents one therapeutic dose or diagnostic dose. •The HCPCS Code effective date represents the date the HCPCS code was established •Procedure codes for covered devices and vaccines are not required to be from a rebating labeler/manufacturer as they are not classified as covered outpatient drugs. HCPCS HCPCS HCPCS Code Billing FDA Approved Indications Max Monthly Gender NDC Rebating Labeler Last Modified Category HCPCS Description Effective Brand Name Generic Name Max Daily Units Minimum Age Maximum Age Comments Code Unit (See Package Insert for full FDA approved indication descriptions) Units Restrictions Required Required Date Date Injection, amphotericin B lipid amphotericin B lipid complex Drugs J0287 10 mg 1/1/2003 Abelcet® Indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. 70 2,170 N/A N/A N/A Y Y 5/6/2019 complex, 10 mg injection aripiprazole extended-release Injection, aripiprazole, Indicated for the treatment of schizophrenia in adults.
    [Show full text]
  • Elevated Plasma Endothelin in Patients with Diabetes Mellitus
    Diabetologia (1990) 33:306-310 Diabetologia Springer-Verlag 1990 Elevated plasma endothelin in patients with diabetes mellitus K. Takahashi, M. A. Ghatei, H.-C. Lam, D. J. O'Halloran and S. R. Bloom Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK Summary. Plasma concentrations of endothelin, a vasocon- noreactive-endothelin showed three forms, one in a very big strictor peptide released from vascular endothelial cells, have molecular weight position, one intermediate and one in the been measured by radioimmunoassay in 100 patients with position of endothelin-1 itself. No material appeared in the diabetes mellitus and 19 healthy subjects. The plasma immu- positions of endothelin-2 and 3. Chromatographic analysis of noreactive-endothelin concentrations were found to be normal plasma showed only the big molecular weight peak greatly raised in the patients with diabetes (I ,880 + 120 fmol/1, while material in the endothelin-1, 2 or 3 positions was below mean + SEM) compared with the healthy subjects (540 + 50 detection. The elevation of endothelin in diabetic patients fmol/1, p < 0.005). The elevation of immunoreactive-endo- may be a marker of, and further exacerbate, their vascular dis- thelin could not be explained by secondary changes in blood ease. pressure or renal disease and did not correlate with the presence of diabetic retinopathy, duration of diabetes melli- Key words: Endothelin, radioimmunoassay, diabetes melli- tus, fasting blood glucose or serum fructosamine. Fast protein tus, fast protein liquid chromatography, endothelial cell, an- liquid chromatographic analysis of the diabetic plasma immu- giopathy. Angiopathy is a major complication in diabetes mellitus [1, Subjects and methods 2].
    [Show full text]
  • Mechanism Development of Diabetic Microangiopathy and Opportunity of Diabetic Warning
    Galician medical journal 2018 Vol. 25, Issue 2, E201828 DOI: 10.21802/gmj.2018.2.8 Review Mechanism Development of Diabetic Microangiopathy and Opportunity of Diabetic Warning S.M. Genyk Abstract Specific general defeat of arteriols, capillaries and veins at a diabet mellitus consists in the bulge of basale membrane of shallow vessels, laying of glycoproteins in a wall and proliferation of endothelium. A hyperglycaemia results in increasing of blood plasma, membranes and cages of level of free radicals on a background insufficiency of enzymes of the protective antioxidant system. Determination of the state insulin tolerance to the people with excessive body weight and obesity, by a hyperpiesis, problems with the lack of fats, by a gout and other endocrine diseases already on the stage of credible violation of carbohydrate exchange gives an opportunity in good time to conduct the correction of possible defeats of microvasculature toxic action of high concentration of glucose. Keywords hyperglycemia; tolerance of insulin; sugaring haemoglobin; microcirculation; diabetic angiopathy Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine Corresponding author: [email protected] A diabetes mellitus DA in the whole world is one of the insulin in the damage of endothelial cages, their disfunction. most widespread chronic diseases and the global medical Thus degree to the hyperglycaemia does not yet cause clinical and economic problem of contemporary or present world symptoms and can exist during the protracted period of time [26]. By the considerable increase of morbidity is the last to the moment of exposure of diabetes mellitus [4, 10]. Ac- decades established on a diabetes mellitus in entire countries tually, an important role of endothelial disfunction is played and on all continents [11, 20].
    [Show full text]
  • Serum Ages and Srage Levels Are Not Related to Vascular Complications in Patients with Prediabetes
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13 (2019) 1005e1010 Contents lists available at ScienceDirect Diabetes & Metabolic Syndrome: Clinical Research & Reviews journal homepage: www.elsevier.com/locate/dsx Original Article Serum AGEs and sRAGE levels are not related to vascular complications in patients with prediabetes * Antoaneta T. Gateva a, , Yavor S. Assyov a, Adelina D. Tsakova b, Zdravko A. Kamenov a a Clinic of Endocrinology, University Hospital “Alexandrovska”, Medical UniversityeSofia, 1 Georgi Sofiiski str, 1431, Sofia, Bulgaria b Central Clinical Laboratory, University Hospital “Alexandrovska”, Medical UniversityeSofia, 1 Georgi Sofiiski str, 1431, Sofia, Bulgaria article info abstract Article history: Background: While hyperglycemia has a key role in the pathogenesis of microvascular complications of Received 15 December 2018 diabetes, it is just one of the many factors contributing to macrovascular damage. The aim of the present Accepted 17 January 2019 study is to investigate the link between serum pentosidine and sRAGE levels and vascular complications in patients with prediabetes compared to normal glucose tolerance controls with obesity. Keywords: Methods: In this study were included 76 patients with mean age 50.7 ± 10.7 years, divided into two age Prediabetes and BMI-matched groups e group 1 with obesity without glycemic disturbances (n ¼ 38) and group 2 Vascular complications with obesity and prediabetes (n ¼ 38). sRAGE fi Pentosidine Results: There was no signi cant difference in pentosidine and sRAGE levels between patients with obesity and prediabetes. Patients with hypertension had lower levels of sRAGE compared to non- hypertensive subjects. sRAGE showed a weak negative correlation to blood glucose on 60th min of OGTT and HOMA index.
    [Show full text]
  • Protective and Anti‑Angiopathy Effects of Ginsenoside Re Against Diabetes Mellitus Via the Activation of P38 MAPK, ERK1/2 and JNK Signaling
    MOLECULAR MEDICINE REPORTS 14: 4849-4856, 2016 Protective and anti‑angiopathy effects of ginsenoside Re against diabetes mellitus via the activation of p38 MAPK, ERK1/2 and JNK signaling YAWEI SHI1, XUESI WAN2, NAN SHAO1, RUNYI YE1, NING ZHANG1 and YUNJIAN ZHANG1 Departments of 1Thyroid and Breast Surgery and 2Endocrinology, The First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510080, P.R. China Received August 30, 2015; Accepted August 9, 2016 DOI: 10.3892/mmr.2016.5821 Abstract. The present study aimed to determine the protec- Introduction tive and anti-angiopathy effects of ginsenoside (GSS) on Wistar rats with diabetes mellitus (DM). Diabetic angiopathy Diabetes mellitus (DM) is a group of metabolic diseases, occurs during the early stage of diabetes, and in type 1 DM which is characterized by chronic hyperglycemia and glucose (T1DM) and type 2 DM (T2DM). In the present study, early intolerance, and may result in multi-organ dysfunction (1). It is DM, T1DM and T2DM were induced by treatment with a one of the most common chronic diseases worldwide, the inci- high-sucrose-high-fat diet, alloxan monohydrate or strep- dence of which is increasing at an alarming rate due to various tozocin, respectively. The levels of blood glucose, insulin, factors (2,3), including increased economic development, lipid metabolism markers [total cholesterol (TC), triglyceride which often leads to changes in diet and lifestyle habits, and (TG), high-density lipoprotein (HDL) and lipoprotein(a) increased obesity (4,5). A previous study reported that >60% (Lp-a)], and endothelial cell function markers [endothelin, of the worldwide population with DM resides in Asia (6).
    [Show full text]
  • Medicines in Development for Diabetes
    2014 MEDICINES IN DEVELOPMENT REPORT Diabetes PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Companies Are Developing 180 Medicines to Treat Diabetes and Related Conditions Nearly 26 million Americans are affected options for patients battling diabetes by diabetes—including 7 million people and diabetes-related conditions. who are unaware they have the disease. Medicines in Development One of the top 10 causes of death in the According to the Centers for Disease For Diabetes United States, diabetes has far-reaching Control and Prevention (CDC), death implications for patients and their fami- rates for people with diabetes fell sub- Application lies and our health care system. stantially—up to 40 percent—between Submitted 1997 and 2006. CDC links this decrease Phase III While healthy eating and exercise can to improved cardiovascular medical Phase II help prevent and manage type 2 diabe- treatment, better management of diabe- tes, medicines play a key role in helping tes, and some healthy lifestyle changes. Phase I reduce the risk of and treat the disease. For example, one medicine was found in Unfortunately, while the death rates due studies to lower the risk by 31 percent. to diabetes are declining, the rate of new cases has been rising. The number of 100 And in recent years, eight new classes of type 2 diabetes medicines have been ap- Americans diagnosed with diabetes has proved by the Food and Drug Administra- more than tripled since 1980, according tion (FDA), giving patients and health care to the CDC. Lifestyle choices can affect providers powerful new options to treat this increase.
    [Show full text]
  • Thesauri on STN: a Useful Tool to Help Ensure Comprehensive Searching
    Thesauri on STN: A useful tool to help ensure comprehensive searching Science IP®, The CAS Search Service. Search requests are often presented in the form of the effect of A on B, where A and B are terms representing concepts. Usually these concepts are described using a variety of synonyms. For comprehensive searching, it is recommended to include multiple synonyms in your strategy for each concept, as appropriate. STN online thesauri are useful in many STN databases to find terms and explore synonyms to strengthen your search strategy. The thesauri are arranged in hierarchical order. You can expand on a search term of interest to find narrow terms (NT), broad terms (BT), use for terms (UF), related terms (RT), etc. Table: Examples of some of the online thesauri on STN for biomedical searches Topic Database Field name Chemistry ZCAPlus lexicon Controlled terms (/CT) Note: Zero hr connect time fees. Biomedical MEDLINE Controlled terms (/CT) Note: known as Medical Subject Headings (MeSH). Chemical name (/CN) Biomedical EMBASE Controlled terms (/CT) Note: known as the Emtree thesaurus. The example shows how synonyms can be found by expanding on a term such as diabetes in the controlled term field (/CT) in ZCAPlus. Diabetes/CT has two associated terms (AT). When you EXPAND on the associated terms, you get the heading term in the thesaurus, in this case, Diabetes mellitus (E14). Example: Expand on Diabetes/CT to find the current heading for Diabetes which is Diabetes Mellitus. Then expand on that term using E E14+ALL. => FILE ZCAPLUS => EXPAND
    [Show full text]
  • PDCO Agenda of the 1-4 September 2020 Meeting
    1 September 2020 EMA/PDCO/439902/2020 Human Medicines Division Paediatric Committee (PDCO) Agenda for the meeting on 1-4 September 2020 Chair: Koenraad Norga – Vice-Chair: Sabine Scherer 1 September 2020, 14:00- 19:00, Virtual meeting 2 September 2020, 08:30- 19:00, Virtual meeting 3 September 2020, 08:30- 19:00, Virtual meeting 4 September 2020, 08:30- 13:00, Virtual meeting Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
    [Show full text]